Consensus Cloud Solutions Announces Closing of New Credit Facility
As of July 14, 2025, no amount had been drawn down on the Credit Facility. The interest rate applicable to the loans made under the Credit Facility are, at the Company's option, equal to either a base rate or the Secured Overnight Financing Rate ('SOFR') plus an applicable margin based on the total net leverage ratio (0.50%-1.25% in the case of base rate loans and 1.50%-2.25% in the case of SOFR loans. The Company expects to draw funds in the last fiscal quarter of 2025 and based on its current leverage would expect an interest rate of SOFR plus an applicable margin of 1.75%. In connection with entering into the Credit Facility, the Company's existing senior secured revolving credit facility agented by U.S. Bank National Association (as successor-in-interest to MUFG Bank, N.A.) was retired without a balance. Further details are provided on the Form 8-K filed by Company on July 14, 2025.
About Consensus Cloud Solutions
Consensus Cloud Solutions, Inc. (NASDAQ-CCSI) is a global leader in digital cloud fax technology. With over 25 years of success with eFax at its core, the company has evolved to be a trusted provider of interoperability solutions, leveraging artificial intelligence and secure data exchange to transform digital information, automate critical workflows, and maximize operational efficiencies. Consensus maintains industry- leading compliance standards, making it a preferred partner for heavily regulated industries including healthcare, the public sector, financial services, insurance, real estate, and manufacturing. For more information about Consensus, visit consensus.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ...
Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Theravance Biopharma Inc (NASDAQ:TBPH) reported a strong quarter with net sales reaching approximately $66 million, driven by demand growth and favorable pricing. The company completed a $225 million sale of its remaining royalty interests in Trilogy to GSK, significantly strengthening its balance sheet. The phase 3 Cypress trial for amproloxetine is progressing well, with enrollment nearing completion and top-line data expected in six months. Theravance Biopharma Inc (NASDAQ:TBPH) ended the quarter with approximately $340 million in cash and no debt, maintaining a strong financial position. The company is on track to achieve significant milestones, including a potential $150 million from royalty Pharma over the next 18 months. Negative Points The company did not provide guidance on the formal launch timing for Upellry in China, as Beatrice is still finalizing the commercialization plan. There is uncertainty regarding the pricing strategy for amproloxetine, as it is still early to determine a specific price point. The company faces challenges in ensuring proper education for clinicians to make the best decisions for patient needs, particularly in specialty pharmacy channels. Theravance Biopharma Inc (NASDAQ:TBPH) expects to pay approximately $27 million in taxes related to the Trilogy royalty sale in the second half of the year. There is potential for pushback on amproloxetine pricing and reimbursement, given the presence of generics with less efficacy and clear side effects. Q & A Highlights Warning! GuruFocus has detected 7 Warning Signs with TBPH. Q: What factors contributed to the improved pull-through performance for Upellary this quarter? A: Rhonda Farnham, Chief Business Officer, explained that the improved pull-through was driven by the transition of volume to specialty pharmacy, which enhances pricing and persistency. The support patients receive in this channel improves fulfillment and persistency compared to conventional retail pharmacy. The company remains focused on providing options that best meet individual patient needs while educating clinicians to make informed decisions. Q: Can you provide an update on the outlook for Upellary's growth in China and the Cyprus trial enrollment? A: Rhonda Farnham stated that Beatrice is leading the commercialization efforts in China, and further details will be shared once their market plan is unveiled. Anya Miller, Head of Development, noted that the Cyprus trial's US versus ex-US enrollment is expected to mirror previous studies, with all data to be disclosed at the topline readout. A press release will be issued upon full enrollment of the open-label portion. Q: How is Theravance Biopharma approaching the pricing strategy for amproloxetine, and what are the considerations for reimbursement in the US? A: Rhonda Farnham mentioned that while it's early to finalize pricing, an analysis of recent rare neuro drug launches suggests an average price of approximately $380,000 per year. The company is actively engaging with payers to highlight the unmet need and the potential benefits of amproloxetine, focusing on its safety profile and durability of effect. Q: What are the expectations for SG&A expenses related to amproloxetine's commercialization, and how might they change post-data readout? A: Aziz Sala, Chief Financial Officer, indicated that SG&A expenses are expected to remain stable through the year, with some pre-launch activities already underway. Post-data readout, if positive, there will be an increase in SG&A spend, but it will be targeted and not excessively large, focusing on supporting the launch and marketing efforts. Q: Can you elaborate on the operating leverage observed in the collaboration revenue growth compared to Upellary's net sales increase? A: Aziz Sala explained that the collaboration revenue growth outpaced net sales growth due to cost reimbursements between the companies. While this quarter showed a significant gap, future quarters may not see the same level of disparity. However, profit margins are expected to continue improving as net sales grow. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Business Insider
20 minutes ago
- Business Insider
Bank of America Securities Sticks to Its Buy Rating for Apple (AAPL)
Bank of America Securities analyst Wamsi Mohan maintained a Buy rating on Apple yesterday and set a price target of $250.00. The company's shares closed yesterday at $229.65. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Mohan is a 5-star analyst with an average return of 13.2% and a 61.64% success rate. Mohan covers the Technology sector, focusing on stocks such as Apple, Seagate Tech, and International Business Machines. In addition to Bank of America Securities, Apple also received a Buy from Goldman Sachs's Mike Ng in a report issued on August 8. However, on August 7, DZ BANK AG maintained a Hold rating on Apple (NASDAQ: AAPL). The company has a one-year high of $260.10 and a one-year low of $169.21. Currently, Apple has an average volume of 56.07M. Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AAPL in relation to earlier this year. Most recently, in May 2025, Chris Kondo, the CAO of AAPL sold 4,486.00 shares for a total of $933,940.34.
Business Insider
20 minutes ago
- Business Insider
Bank of America Securities Sticks to Its Buy Rating for Liquidia Technologies (LQDA)
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Liquidia Technologies yesterday and set a price target of $35.00. The company's shares closed yesterday at $24.10. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Gerberry covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Liquidia Technologies, and BioMarin Pharmaceutical. According to TipRanks, Gerberry has an average return of 2.5% and a 48.57% success rate on recommended stocks. In addition to Bank of America Securities, Liquidia Technologies also received a Buy from LifeSci Capital's Cory Jubinville, PhD in a report issued yesterday. However, on July 29, Oppenheimer maintained a Sell rating on Liquidia Technologies (NASDAQ: LQDA). Based on Liquidia Technologies' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.12 million and a GAAP net loss of $38.37 million. In comparison, last year the company earned a revenue of $2.97 million and had a GAAP net loss of $40.93 million
